** Biotech firm Bio-Techne's TECH.O shares rise 4.8% to $76 premarket
** TECH beat Q2 earnings estimates, driven by growth in its protein sciences unit that develops biological compounds for research, diagnostics, and cell and gene therapy
** The protein sciences unit's sales rose 7% to $211.6 mln
** Company reports Q2 adj profit of 42 cents per share, above analysts' est of 39 cents - LSEG
** Posts Q2 sales of $297 mln, above analysts' est of $285.7 mln - LSEG
** TECH fell ~6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。